2025-05-15-Jefferies-因希比凯治疗公司（IKT）_第一季度肺动脉高压（PAH）IIB期试验将于2025年下半年启动_9页_892kb

USA Biotechnology Equity Research: Inhibikase Therapeutics (IKT)

Q1 Key Developments:

• Phase IIB trial for PAH (Pulmonary Arterial Hypertension) is set to initiate in H2:25 (with trial design finalization expected in coming weeks).
• Current market cap is approximately $189.7M, with a share price of $2.12. The 12-month price target ranges from $8.00 (est. +277% upside) to $15.00 (+608% upside), while a downside scenario is $1.00 (-53%).
• New management changes reflect a pivot from neurology (Parkinson's) to cardiovascular focus.

Product Pipeline:

• IKT-001Pro: An oral imatinib pro-drug designed for improved tolerability in PAH. Previous imatinib trials showed efficacy but were halted due to safety concerns. PAH could be a $1-2B opportunity if compelling efficacy is demonstrated. Preclinical data suggest improved safety compared to historical trials, which had 25-30% discontinuation rates and failed to reach target doses.
• Risvodetinib: A Parkinson's drug candidate with no current valuation assigned by the firm due to higher clinical risk.

Financials:

• $93M in cash, supporting operations through 2027 based on warrant proceeds.
• No revenue expected until at least 2025. Projected EPS is negative in FY 2025 and 2026.

Investment Thesis:

• IKT’s stock is considered undervalued given the potential for $1-2B peak sales in PAH.
• Key risks include clinical trial delays, commercial acceptance challenges (especially for rare diseases), and high volatility.

Other Key Points:

• Sustainability considerations are an important aspect, including issues related to product affordability.
• The CEO, CFO, and CSO have recently changed, reflecting strategic shifts.
• The firm rated IKT "BUY," with high upside potential but also significant risk.

This report provides earnings-based and equity research related to Inhibikase Therapeutics, focusing on its pipeline, management changes, and potential market opportunities.